Anne Rancourt Named Director of Health Communication at FDA CTP

News by 2FIRSTS.ai
Apr.10.2024
Anne Rancourt Named Director of Health Communication at FDA CTP
Anne Rancourt named next director of CTP's Health Communication and Education Office by FDA, effective May 19.

The U.S. Food and Drug Administration (FDA) subsidiary Tobacco Products Center (CTP) recently announced that Anne Rancourt has been selected as the next director of the Office of Health Communication and Education. Rancourt previously served as the Communications Director at the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH).

 

Lungkul has over 20 years of experience in strategic communications, behavior change projects, and news fields, including nearly 14 years of work in the federal government. She managed the communication department at NIDA, overseeing the dissemination of research findings on substance use and addiction worth nearly $2 billion, including tobacco and e-cigarette use. Prior to this, she also served as the Chief of Communications Science at the National Institute of Allergy and Infectious Diseases (NIAID).

 

CTP stated that Lankhul has been selected after undergoing a thorough nationwide search and passing the important ethical and safety review process by the FDA. She will take office on May 19th.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International (PMI) said its U.S.-related investments have topped $20 billion since 2022, when it entered the U.S. market through its roughly $19 billion acquisition of Swedish Match. The company also said it plans to launch its heated tobacco product IQOS ILUMA in the United States pending authorization from the U.S. Food and Drug Administration (FDA).
Jan.16 by 2FIRSTS.ai
China to Cancel VAT Export Rebates on E-Cigarette Products from April 1, 2026
China to Cancel VAT Export Rebates on E-Cigarette Products from April 1, 2026
China’s Ministry of Finance and State Taxation Administration have announced adjustments to export tax rebate policies, placing nicotine-containing non-combustible inhalation products within the scope of items subject to rebate cancellation. The measures will take effect from April 1, 2026.
Regulations
Jan.10
BAT Japan rolls out limited-edition “Rose Quartz” colourway for glo Hilo, launches new virto click-capsule flavour
BAT Japan rolls out limited-edition “Rose Quartz” colourway for glo Hilo, launches new virto click-capsule flavour
British American Tobacco (BAT) Japan will introduce its first Valentine’s-season limited-edition colourway, “Rose Quartz,” for the glo Hilo heated tobacco device lineup, covering both the glo Hilo and glo Hilo Plus. The devices are priced at JPY 3,980 (about $25.2) and JPY 6,980 (about $44.1), respectively, and will go on sale via official channels from Feb. 9. BAT Japan will also launch a new glo Hilo-compatible virto tobacco stick variant, “virto Bright Cherry Click,” on Feb. 2.
Jan.20 by 2FIRSTS.ai
Guam checks 277 eligible retailers in 2025; eight found selling tobacco or disposable vapes to minors aged 16–20
Guam checks 277 eligible retailers in 2025; eight found selling tobacco or disposable vapes to minors aged 16–20
he Guam Behavioral Health and Wellness Center said that out of 277 eligible tobacco retailers inspected in 2025, eight were found selling tobacco or disposable e-cigarettes or vapes to minors aged 16–20, and one retailer failed to display the required “No Sale Under 21” prohibition sign.
Jan.05 by 2FIRSTS.ai
Swedish Match to Revamp ZYN Lineup, Discontinue Four Nicotine Pouch Products in 2026
Swedish Match to Revamp ZYN Lineup, Discontinue Four Nicotine Pouch Products in 2026
According to Swedish Match’s website, the company plans to discontinue four ZYN nicotine pouch products in 2026, spanning different flavors and strength variants, and is directing consumers to existing substitute options.
Dec.19 by 2FIRSTS.ai
Alan Zhao: What Altria’s on! PLUS Authorization Really Signals About FDA PMTA Enforcement
Alan Zhao: What Altria’s on! PLUS Authorization Really Signals About FDA PMTA Enforcement
In this in-depth commentary for 2Firsts, Alan Zhao examines what Altria’s on! PLUS authorization really signals about FDA PMTA enforcement. Beyond the headline approval, FDA’s language, process design and product choices offer rare insight into how nicotine pouch regulation is taking shape—and what it means for industry compliance, in one of the earliest expert reads of the decision.
Regulations
Dec.20 by 2Firsts Perspectives